Policy & Regulation
Actuate Therapeutics advances elraglusib tablet into Phase 1/2 trial for refractory cancers
21 January 2026 - US clinical-stage biopharmaceutical company Actuate Therapeutics Inc (NASDAQ:ACTU) on Wednesday announced plans to initiate a Phase 1/2 clinical program evaluating its oral elraglusi...
EU approves DAWNZERA for hereditary angioedema
21 January 2026 - Ionis Pharmaceuticals Inc (Nasdaq:IONS), a US-based provider of RNA-targeted medicines, and Japanese healthcare company Otsuka Pharmaceutical Co Ltd on Wednesday announced that the E...
Charles River collaborates with Gazi University on rare disease gene therapy research
21 January 2026 - Pharmaceutical research services provider Charles River Laboratories International Inc (NYSE:CRL) announced on Wednesday that it has entered into a collaboration with Gazi University...
Avacta secures FDA clearance for second pre|CISION oncology programme
21 January 2026 - Biopharmaceutical company Avacta Group PLC (AIM: AVCT) announced on Wednesday that it has received clearance from the U.S. Food and Drug Administration of the Investigational New Dru...
LEO Pharma advances delgocitinib cream into phase 3 trial for lichen sclerosus
21 January 2026 - Danish pharmaceutical company LEO Pharma A/S said on Wednesday that it has initiated the phase 3 DELTA CARE 1 trial to evaluate the efficacy and safety of Anzupgo (delgocitinib) crea...
Syngene International and Bristol Myers Squibb extend collaboration to 2035
21 January 2026 - Syngene International, an India-based global contract research, development, and manufacturing organisation (CRDMO), announced on Tuesday that it has extended its long-standing strat...